<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03433937</url>
  </required_header>
  <id_info>
    <org_study_id>S-20170085</org_study_id>
    <nct_id>NCT03433937</nct_id>
  </id_info>
  <brief_title>Prevention of Seroma Following Inguinal Lymph Node Dissection With Prophylactic Incisional Negative Pressure Wound Therapy</brief_title>
  <official_title>Prevention of Seroma Following Inguinal Lymph Node Dissection With Prophylactic Incisional Negative Pressure Wound Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Odense University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Odense University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Inguinal lymph node dissection (ILND) is indicated following metastatic malignant melanoma,
      and is associated with a high-complication rate, of which many begin with the formation of
      seroma and ends in complicated wound healing, reoperation, multiple outpatient visits and
      re-hospitalization. Prevention of seroma may therefore lead to a reduction of many of the
      preceding complications and improve patient quality-of-life. The aim of this study is to
      evaluate the efficacy and oncological safety of prophylactic negative pressure wound therapy
      following ILND in melanoma patients.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2018</start_date>
  <completion_date type="Anticipated">March 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with seroma</measure>
    <time_frame>3 months</time_frame>
    <description>One or more inguinal seroma(s) which require aspiration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of seromas for each participant</measure>
    <time_frame>3 months</time_frame>
    <description>Number of aspirated seromas (No.)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of seromas for each participant</measure>
    <time_frame>3 months</time_frame>
    <description>Volume of aspirated seromas (mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with surgical wound infection</measure>
    <time_frame>3 months</time_frame>
    <description>Inguinal wound infection which require antibiotic treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with wound rupture</measure>
    <time_frame>3 months</time_frame>
    <description>Inguinal wound rupture which require addition suturing or NPWT treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with wound necrosis</measure>
    <time_frame>3 months</time_frame>
    <description>Inguinal wound necrosis which require debridement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with hematoma</measure>
    <time_frame>3 months</time_frame>
    <description>Inguinal wound hematoma which require evacuation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Questionnaire EQ-5D-5L</measure>
    <time_frame>Baseline, 3 months and 2 years</time_frame>
    <description>Quality of life measurement score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization time</measure>
    <time_frame>3 months</time_frame>
    <description>Length of hospital stay until discharge (days)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization readmission time</measure>
    <time_frame>3 months</time_frame>
    <description>Length of hospital readmissions (days)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with reoperations</measure>
    <time_frame>3 months</time_frame>
    <description>Re-operation with opening of the wound or scar under general anesthesia due to adverse complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with lymphedema</measure>
    <time_frame>2 years</time_frame>
    <description>Clinical evaluation using the International Lymphedema Society staging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Questionnaire LYMQOL</measure>
    <time_frame>2 years</time_frame>
    <description>Lymphedema quality of life measurement score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with regional recurrence</measure>
    <time_frame>2 years</time_frame>
    <description>Histological verified recurrence to the inguinal site</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Seroma</condition>
  <condition>Surgical Site Infection</condition>
  <condition>Lymphedema</condition>
  <condition>Quality of Life</condition>
  <arm_group>
    <arm_group_label>Negative pressure wound therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Micropore tape</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Negative pressure wound therapy</intervention_name>
    <description>Wound dressing</description>
    <arm_group_label>Negative pressure wound therapy</arm_group_label>
    <other_name>vacuum assisted closure</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Micropore tape</intervention_name>
    <description>Wound dressing</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All malignant melanoma patients who are candidates for ILND and 18 years of age or
             older

        Exclusion Criteria:

          -  Patients suspected of having tumor residuals after ILND, previous groin irradiation or
             patients suffering from dementia or any psychiatric disorder making them incapable of
             informed consent or adherence to follow up, along with patients who are unable to
             communicate in Danish or English will not be included in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jens A Sørensen</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Plastic Surgery, Odense University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mads G Jørgensen</last_name>
    <phone>22163425</phone>
    <phone_ext>+45</phone_ext>
    <email>Mads.Gustaf.Jorgensen@rsyd.dk</email>
  </overall_contact>
  <reference>
    <citation>Jørgensen MG, Toyserkani NM, Thomsen JB, Sørensen JA. Surgical-site infection following lymph node excision indicates susceptibility for lymphedema: A retrospective cohort study of malignant melanoma patients. J Plast Reconstr Aesthet Surg. 2018 Apr;71(4):590-596. doi: 10.1016/j.bjps.2017.11.026. Epub 2017 Nov 28.</citation>
    <PMID>29246739</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 30, 2018</study_first_submitted>
  <study_first_submitted_qc>February 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 15, 2018</study_first_posted>
  <last_update_submitted>March 19, 2018</last_update_submitted>
  <last_update_submitted_qc>March 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Odense University Hospital</investigator_affiliation>
    <investigator_full_name>Mads Gustaf Jørgensen</investigator_full_name>
    <investigator_title>Mr.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphedema</mesh_term>
    <mesh_term>Surgical Wound Infection</mesh_term>
    <mesh_term>Seroma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

